ArticleCureus2025
Radiofrequency Ablation of Benign Thyroid Nodules: Preliminary Outcomes of an Endocrine Surgery Unit.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Radiofrequency ablation (RFA) is a minimally invasive alternative for the management of benign thyroid nodules in patients with symptomatic or enlarging lesions who seek to avoid the risks and morbidity associated with surgery. Our aim was to evaluate the initial RFA results of our endocrine surgery unit. Methods We analyzed our early RFA outcomes from November 2022 to November 2024. The VIVA RF system (STARmed Co. Ltd., Goyang-si, GG, KOR) was used, with an internally cooled 18-gauge electrode and a 10-mm active tip. The ultrasound (US)-guided trans-isthmic approach and the moving-shot technique were used in all patients after two confirmed Bethesda II cytologies. Results We identified 33 cases, mostly women (93.9%), with a mean age of 54 years old. Surgical indications were restricted to compressive symptoms (19/33, 57.6%), cosmesis (4/33, 12.1%), or both (10/33, 30.3%). The nodules were classified per the European Thyroid Imaging and Reporting Data System (EU-TIRADS): category 2 (2/33, 6.1%), category 3 (25/33, 75.8%), and category 4 (6/33, 19.2%). The average nodule volume was 12 mL. The mean energy delivered and duration were 16150 J (± 10836) and 7.2 min (± 4.3), respectively. We report three cases (9.0%) of postoperative morbidity: a subcutaneous hematoma, a Horner syndrome, and a patient with transient hoarseness. At three months, the mean volume reduction ratio (VRR) was 40.4%, while the six-month VRR was 47.1%. Conclusion Our initial experience demonstrated a near 50% volume reduction at six months. The RFA's low complication rate, coupled with the freedom to perform the procedure with local anesthesia, makes it an attractive option. Regrowth and the need for reintervention are possible. Further follow-up is necessary to assess long-term efficacy and recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.